Unveils 2020 Original and Exclusive ProgrammingIntroduces New Ad Technology That Enhances Revenue and Improves Customer ExperienceExpands Distribution for Crackle and […]
Preclinical data on XMT-1592, a NaPi2b-targeted site-specific and homogeneous Dolasynthen ADC, demonstrate excellent activity, tolerability and pharmacokineticsPreclinical data on multiple […]
SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation […]